"Most worryingly, it turns out that there was a clear difference between the placebo group and the treatment group in APOE4 status." I would turn to Derek Lowe

"Most worryingly, it turns out that there was a clear difference between the placebo group and the treatment group in APOE4 status." I would turn to Derek Lowe as he is an expert in the field who has been looking forward to this release... he holds out hope, but is not positive on "the field is in the state it’s in today." http://blogs.sciencemag.org/pipeline/archives/2018/07/26/biogen-and-eisai-let-the-alzheimers-arguing-commence http://blogs.sciencemag.org/pipeline/archives/2018/07/26/bio... "APOE4, a lipoprotein, has been recognized as a risk factor for Alzheimer’s since back in the 1990s, although the mechanism behind that has been the subject of debate. But there was a regulatory-mandated change in enrollment of APOE4 patients during the (Bayesian) trial, for fear of a brain-swelling side effect that these patients are also prone to, and there ended up being far more APOE4-positive patients in the placebo group compared to the high-dose group (70% versus 30%)."